Table of contents
Executive summary
Portfolio
Antifungal Cresemba® (isavuconazole)
Antibiotic Zevtera® (ceftobiprole)
Oncology
Derazantinib
Lisavanbulin
BAL0891
Financials & Outlook
Appendix
Focused on Growth and Innovation
Confidential/proprietary information of Basilea Pharmaceutica International Ltd. - not for distribution
Experienced leadership team
Focused on Growth and Innovation
Confidential/proprietary information of Basilea Pharmaceutica International Ltd. - not for distribution
At a glance
Well funded, commercial-stage biopharmaceutical company with significantly growing cash flows from commercialized products
Focused in the areas of anti-infectives and oncology
Potential for sustainable growth and value creation based on commercialized brands and an innovative pipeline
Experienced people with the proven expertise to take compounds from research to market
Two revenue generating hospital anti-infective brands, Cresemba® and Zevtera® and three oncology drug candidates
Recognized ability to establish and manage partnerships in both the development and commercial phase, providing access to international markets
Listed on SIX Swiss Stock Exchange, SIX: BSLN
Based in life sciences hub, Basel, Switzerland
Focused on Growth and Innovation
Confidential/proprietary information of Basilea Pharmaceutica International Ltd. - not for distribution
This is an excerpt of the original content. To continue reading it, access the original document here.
Attachments
- Original Link
- Original Document
- Permalink
Disclaimer
Basilea Pharmaceutica AG published this content on 30 March 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 30 March 2022 13:52:05 UTC.